The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 24, 2018

Filed:

Jun. 29, 2015
Applicant:

Revance Therapeutics, Inc., Newark, CA (US);

Inventor:

Gary E. Borodic, Quincy, MA (US);

Assignee:

REVANCE THERAPEUTICS, INC., Newark, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/48 (2006.01); A61K 8/02 (2006.01); A61K 8/24 (2006.01); A61K 8/33 (2006.01); A61K 8/55 (2006.01); A61K 8/64 (2006.01); A61K 8/65 (2006.01); A61K 8/81 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/08 (2006.01); A61K 47/10 (2017.01); A61K 47/24 (2006.01); A61K 47/32 (2006.01); A61K 47/42 (2017.01); A61Q 19/08 (2006.01); A61K 8/66 (2006.01);
U.S. Cl.
CPC ...
A61K 38/4833 (2013.01); A61K 8/02 (2013.01); A61K 8/24 (2013.01); A61K 8/33 (2013.01); A61K 8/553 (2013.01); A61K 8/64 (2013.01); A61K 8/65 (2013.01); A61K 8/66 (2013.01); A61K 8/8111 (2013.01); A61K 8/8141 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 38/4893 (2013.01); A61K 47/08 (2013.01); A61K 47/10 (2013.01); A61K 47/24 (2013.01); A61K 47/32 (2013.01); A61K 47/42 (2013.01); A61Q 19/08 (2013.01); A61K 2800/48 (2013.01); A61K 2800/5922 (2013.01); A61K 2800/91 (2013.01); C12Y 304/21005 (2013.01); C12Y 304/24069 (2013.01);
Abstract

An extended duration pharmaceutical composition including a botulinum neurotoxin, an adhesive agent, and a stabilizing macromolecule is disclosed. The composition effectively has all the properties to cause chemodenervation through a facial muscle, or other muscle, that predecessor botulinum toxin preparations have had as well as agents which create a fibrotic adhesion on the under surface of facial muscles (or other muscles) to the facial bone (or other bones) so that the facial bone tethers the under surface of the facial muscle, thereby causing fibrosis to the underlying fat pad. The composition can be used to treat various disorders. Methods of modifying facial contour for functional or cosmetic purposes in a human patient are disclosed which involve injecting a therapeutically effective amount of the disclosed compositions. A method of quantifying the extended duration of the compositions is also disclosed.


Find Patent Forward Citations

Loading…